Multiplex immunofluorescence microscopy assays for pharmacodynamic assessment of MET tyrosine kinase activation in the plasma membrane and nucleus.
Saved in:
| Title: | Multiplex immunofluorescence microscopy assays for pharmacodynamic assessment of MET tyrosine kinase activation in the plasma membrane and nucleus. |
|---|---|
| Authors: | Navas T; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Srivastava AK; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Lawrence SM; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Hollingshead MG; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Alcoser SY; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Miller SB; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Bottaro DP; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Linehan WM; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America. |
| Source: | PloS one [PLoS One] 2026 May 12; Vol. 21 (5), pp. e0349090. Date of Electronic Publication: 2026 May 12 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0349090 |
